Mutants of the P4 protein of nontypable
View Patent ↗A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable H. influenzae (NTHi) is useful as an active component in an immunogenic composition for humans. Methods of using these proteins, and compositions containing them in combination with additional antigens, are also provided.
1. An isolated nucleotide molecule comprising a nucleic acid sequence that has at least 90% identity to a nucleic acid sequence encoding a P4 variant protein of NTHi that has reduced phosphatase activity compared to wild-type P4 protein and that induces antibody to wild-type P4 protein, said antibody having bactericidal activity against NTHi, wherein the P4 variant protein has a mutation selected from the group consisting of:
(a) a glutamic acid, aspartic acid or asparagine in place of glutamine at wild-type amino acid residue 39 of SEQ ID NO:3;
(b) a cysteine, serine or other amino acids which have uncharged polar groups in place of phenylalanine at wild-type amino acid residue 48 of SEQ ID NO:3;
(c) an asparagine, glutamic acid or alanine in place of aspartic acid at wild-type amino acid residue 64 of SEQ ID NO:3;
(d) an arginine in place of lysine at wild-type amino acid residue 161 of SEQ ID NO:3;
(e) a glutamine, aspartic acid or glutamic acid in place of asparagine at wild-type amino acid residue 218 of SEQ ID NO:3;
(f) an asparagine in place of alanine at wild-type amino acid residues 35 and 37 of SEQ ID NO:3;
(g) an alanine, asparagine or glutamic acid in place of aspartic acid at wild-type amino acid residues 64 and 66 of SEQ ID NO:3; and
(h) combinations of one or more of the mutations of (a)-(g),
where the nucleic acid sequence encodes at least one of the mutations of (a)-(g).
2. The isolated nucleotide molecule according to claim 1 , wherein said nucleic acid sequence is under the control of regulatory sequences that direct expression of the P4 variant in a host cell.
3. An isolated nucleotide molecule comprising a nucleic acid sequence that has at least 90% identity to a nucleic acid sequence encoding a P4 variant protein of NTHi that has reduced phosphatase activity compared to wild-type P4 protein and that induces antibody to wild-type P4 protein, said antibody having bactericidal activity against NTHi, wherein the P4 variant protein consists of amino acids at positions 1-200, 1-210, 1-221 or 1-232 of SEQ ID NO: 3.
4. The isolated nucleotide molecule according to claim 3 , wherein the nucleic acid molecule encodes said P4 variant protein having a mutation selected from the group consisting of:
(a) a mutation at amino acid residue 39 of SEQ ID NO:3, which is a glutamine in wild-type P4 protein;
(b) a mutation at amino acid residue 48 of SEQ ID NO:3, which is a phenylalanine in wild-type P4 protein;
(c) a mutation at amino acid residue 64 of SEQ ID NO:3, which is an aspartic acid in wild-type P4 protein;
(d) a mutation at amino acid residue 161 of SEQ ID NO:3, which is a lysine in wild-type P4 protein;
(e) a mutation at amino acid residue 218 of SEQ ID NO:3, which is an asparagine in wild-type P4 protein;
(f) mutations at amino acid residues 35 and 37 of SEQ ID NO:3, which are alanine in wild-type P4 protein, where the mutations are not glutamic acid, glutamine or threonine;
(g) mutations at amino acid residues 64 and 66 of SEQ ID NO:3, which are aspartic acid in wild-type P4 protein; and
(h) combinations of one or more of the mutations of (a)-(g),
where the nucleic acid sequence encodes at least one of the mutations of (a)-(g).
5. An isolated nucleotide molecule comprising a nucleic acid sequence that has at least 90% identity to a nucleic acid sequence encoding a P4 variant protein of NTHi that has reduced phosphatase activity compared to wild-type P4 protein and that induces antibody to wild-type P4 protein, said antibody having bactericidal activity against NTHi, wherein the P4 variant protein consists of amino acids at positions 1-200, 1-210, 1-221 or 1-232 of SEQ ID NO: 3 and the P4 variant protein further having a mutation selected from the group consisting of:
(a) a glutamic acid, aspartic acid or asparagine in place of glutamine at wild-type amino acid residue 39 of SEQ ID NO:3;
(b) a cysteine, serine or other amino acids which have uncharged polar groups in place of phenylalanine at wild-type amino acid residue 48 of SEQ ID NO:3;
(c) an asparagine, glutamic acid or alanine in place of aspartic acid at wild-type amino acid residue 64 of SEQ ID NO:3;
(d) an arginine in place of lysine at wild-type amino acid residue 161 of SEQ ID NO:3;
(e) a glutamine, aspartic acid or glutamic acid in place of asparagine at wild-type amino acid residue 218 of SEQ ID NO:3;
(f) an asparagine in place of alanine at wild-type amino acid residues 35 and 37 of SEQ ID NO:3;
(g) an alanine, asparagine or glutamic acid in place of aspartic acid at wild-type amino acid residues 64 and 66 of SEQ ID NO:3; and
(h) combinations of one or more of the mutations of (a)-(g), where the nucleic acid sequence encodes at least one of the mutations of (a)-(g).
6. The isolated nucleotide molecule according to claim 5 , wherein said molecule is a plasmid vector.
7. A host cell transformed, transfected or transduced with the plasmid vector of claim 6 .
8. The isolated nucleotide molecule according to claim 1 , wherein said molecule is a plasmid vector.
9. A host cell transformed, transfected or transduced with the plasmid vector of claim 8 .
10. The isolated nucleotide molecule according to claim 3 , wherein said molecule is a plasmid vector.
11. A host cell transformed, transfected or transduced with the plasmid vector of claim 10 .
12. An immunogenic composition comprising a nucleotide molecule of claim 5 and a pharmaceutically acceptable carrier.
13. An immunogenic composition comprising a nucleotide molecule of claim 1 and a pharmaceutically acceptable carrier.
14. An immunogenic composition comprising a nucleotide molecule of claim 3 and a pharmaceutically acceptable carrier.
15. A method for inducing an immune response in a human against non-typable H. influenzae comprising the steps of:
administering to said human an effective amount of the immunogenic composition of claim 12 .
16. A method for inducing an immune response in a human against non-typable H. influenzae comprising the steps of:
administering to said human an effective amount of the immunogenic composition of claim 13 .
17. A method for inducing an immune response in a human against non-typable H. influenzae comprising the steps of:
administering to said human an effective amount of the immunogenic composition of claim 14 .
18. A method for producing a P4 variant protein which comprises culturing the host cell of claim 7 under conditions suitable to produce the P4 variant protein and recovering the P4 variant protein from the culture.
19. A method for producing a P4 variant protein which comprises culturing the host cell of claim 9 under conditions suitable to produce the P4 variant protein and recovering the P4 variant protein from the culture.
20. A method for producing a P4 variant protein which comprises culturing the host cell of claim 11 under conditions suitable to produce the P4 variant protein and recovering the P4 variant protein from the culture.
21. The isolated nucleotide molecule according to claim 3 , wherein said nucleic acid sequence is under the control of regulatory sequences that direct expression of the P4 variant in a host cell.
22. The isolated nucleotide molecule according to claim 5 , wherein said nucleic acid sequence is under the control of regulatory sequences that direct expression of the P4 variant in a host cell.